Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2024

What’s on the horizon for metastatic prostate cancer patients?

B7-H3 as therapeutic target for PC

Date

14 Sep 2024

Session

What’s on the horizon for metastatic prostate cancer patients?

Topics

Translational Research;  Immunotherapy

Tumour Site

Prostate Cancer

Presenters

Juliet Carmichael

Authors

J. Carmichael

Author affiliations

  • Division Of Clinical Studies, Prostate Cancer Targeted Therapies Group, The Royal Marsden Hospital - NHS Foundation Trust, SW3 6JJ - London/GB

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

T cell engagers in prostate cancer

Presenter: Neeraj Agarwal

Session: What’s on the horizon for metastatic prostate cancer patients?

Resources:

Slides

Webcast

Targeting epigenetic pathways

Presenter: Wilbert Zwart

Session: What’s on the horizon for metastatic prostate cancer patients?

Resources:

Slides

Webcast

Q&A and discussion

Session: What’s on the horizon for metastatic prostate cancer patients?

Resources:

Webcast

Conclusions and perspectives

Presenter: Karim Fizazi

Session: What’s on the horizon for metastatic prostate cancer patients?

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.